Investigational Drug Details
| Drug ID: | D519 |
| Drug Name: | AstraZeneca |
| Synonyms: | A Novel AstraZeneca Compound; AZ compound |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 terminated (NCT02605616: Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0111 | NCT02826525 | Phase 1 | Completed | No Results Available | July 18, 2016 | April 1, 2021 | Details |
| L0146 | NCT02354976 | Phase 2 | Completed | Has Results | September 1, 2015 | September 25, 2018 | Details |
| L0232 | NCT04483947 | Phase 1 | Recruiting | No Results Available | 06/07/2020 | 24 January 2022 | Details |
| L0295 | NCT05143905 | Phase 1 | Recruiting | No Results Available | December 6, 2021 | March 15, 2022 | Details |
| L0315 | NCT02612662 | Phase 1 | Active, not recruiting | No Results Available | November 24, 2015 | December 14, 2021 | Details |
| L0344 | NCT04142424 | Phase 1 | Completed | No Results Available | October 28, 2019 | November 26, 2021 | Details |
| L0366 | NCT02279407 | Phase 2 | Completed | Has Results | January 2015 | March 17, 2017 | Details |
| L0601 | NCT02605616 | Phase 2 | Not recruiting | No Results Available | 18/09/2015 | 12 December 2020 | Details |
| L0623 | EUCTR2014-003638-26-SE | Not applicable | Not Recruiting | No Results Available | 03/10/2014 | 11 April 2016 | Details |
| L0929 | NCT01703260 | Phase 2 | Not recruiting | Has Results | 02/10/2012 | 19 October 2017 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A05221 | 33334026 | Int J Mol Sci | Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation. | Details |
| A13443 | 29971527 | Diabetologia | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. | Details |